Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's AOCI?
- BioMarin Pharmaceuticals (BMRN) reported AOCI of -$8.78M in Q2 2026.
- How has BioMarin Pharmaceuticals's AOCI changed year-over-year?
- BioMarin Pharmaceuticals's AOCI increased by 80.3% year-over-year, from -$44.57M to -$8.78M.
- What is the long-term trend for BioMarin Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's AOCI has grown at a -3.5% compound annual growth rate (CAGR), from -$16.14M to -$13.47M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about BioMarin Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude